OBI 's ADC Technology Platform GlycOBI® and Enzyme EndoSymeOBI® Two Trademarks Approved by Taiwan Intellectual Property Office

On July 5th, OBI Pharma, Inc. (4174.two) received notification from the Taiwan Intellectual Property Office under the Ministry of Economic Affairs that trademarks for the Antibody-Drug Conjugate (ADC) technology platform GlycOBI® and the enzyme EndoSymeOBI® have been approved. Both were independently developed by OBI Pharma. These approvals will provide stronger protection for OBI Pharma’s innovative […]